Core Viewpoint - The company is actively implementing a strategy focused on major traditional Chinese medicine (TCM) products and brands, leading to steady growth in its TCM segment [1] Group 1: Company Strategy - The company is committed to the deep implementation of a major TCM product and brand strategy [1] - The company has made significant progress in evidence-based medical research for key TCM products such as Wei Fu Chun and Guan Xin Ning [1] Group 2: Mergers and Acquisitions - The successful acquisition of Shanghai He Huang has enabled the company to obtain excellent products like She Xiang Bao Xin Wan and Dan Ning Pian, along with several Class 1 new drugs in development [1] - The acquisition has facilitated synergy in the industrial chain, channel network, and marketing promotion, enhancing the company's TCM business for higher quality development [1]

Core Viewpoint - Shanghai Pharmaceuticals has leveraged its existing channel network to provide compliant contract sales services for pharmaceutical companies, enabling them to expand their market presence in a cost-effective manner [1] Group 1 - The company has established a rigorous compliance management system and professional business capabilities, resulting in a strong brand reputation [1] - By 2025, the company aims to achieve strategic partnerships with multiple pharmaceutical firms, enhancing both service scale and service capability [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 致：香港交易及結算所有限公司 公司名稱: 上海醫藥集團股份有限公司 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02607 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 919,072,704 | RMB | | 1 RMB | | 919,072,704 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 919,072,704 | RMB | | 1 RMB | | 919,072,70 ...

Group 1 - The core point of the announcement is that Shanghai Pharmaceuticals has received a drug registration certificate from the Philippines Food and Drug Administration for its Pregabalin capsules, allowing the product to be marketed in the Philippines [1][4]. Group 2 - The drug is named Pregabalin capsules, available in dosages of 50mg, 75mg, and 150mg, and is classified as a chemical generic drug [1]. - Pregabalin capsules are primarily used for treating postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, spinal cord injury-related neuropathic pain, and as an adjunctive treatment for epilepsy [1]. Group 3 - The development of Pregabalin capsules was completed by Changzhou Pharmaceutical Factory in October 2019, and the product received FDA approval in the United States in July 2021. It also obtained drug registration certificates in Thailand in June 2025 and Singapore in January 2026 [2]. Group 4 - As of the end of 2024, there are 19 distributors of Pregabalin capsules in the Philippines, including UNILAB, VIATRIS INC, and NATRAPHARM. The total sales amount for the three dosages in the Philippines market is projected to be $13.37 million [3].

Regulatory Updates - In 2025, the National Medical Products Administration (NMPA) received 457 special approval applications for innovative medical devices, with 104 approved for special review and 38 priority applications, of which 26 were granted priority approval [1] - By the end of 2025, 475 traditional Chinese medicine production bases passed inspections, covering nearly 1.24 million acres and providing 101 types of Chinese medicinal materials for 215 production enterprises [2] Company Announcements - Shanghai Pharmaceuticals announced that its pregabalin capsules received a drug registration certificate from the Philippines, with a total sales amount of $13.37 million for three specifications [2] - Jiukang Bio received a medical device registration certificate for its albumin assay kit, valid until February 12, 2031 [3] Clinical Research - Eli Lilly's orforglipron demonstrated superior efficacy in glycemic control and weight loss compared to oral semaglutide in a head-to-head study involving 1,698 participants [4][5] - The study results were published in The Lancet, indicating significant improvements in A1C and weight reduction with orforglipron [5] Financial Performance - Baili Tianheng reported a net loss of 1.051 billion yuan for 2025, a significant decline from the previous year, with total revenue of 2.520 billion yuan, down 56.72% [8] - Junshi Biosciences achieved a total revenue of 2.498 billion yuan in 2025, a year-on-year increase of 28.23%, but reported a net loss of 874 million yuan [8] - Yifang Bio reported a net loss of 317 million yuan for 2025, with total revenue of 37.3253 million yuan, down 77.89% [9] - Nanmo Bio's total revenue for 2025 was 421.2586 million yuan, up 10.50%, with a net profit increase of 399.29% to 32.4313 million yuan [10]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the Philippines Food and Drug Administration for the marketing of its pregabalin capsules, indicating a significant milestone for the company in expanding its product offerings in international markets [1] Group 1 - The company announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., has successfully obtained a drug registration certificate for pregabalin capsules [1] - The approval marks a key step in the company's strategy to enhance its presence in the pharmaceutical market of the Philippines [1]

Group 1: Company Performance - Cambrian achieved a net profit of 2.059 billion yuan in 2025, turning a profit due to a significant increase in revenue, which reached 6.497 billion yuan, a 453.21% increase year-on-year [1] - Muxi reported a total revenue of 1.644 billion yuan in 2025, a 121.26% increase, with net losses narrowing by 44.53% to 781.45 million yuan [2] - Moer Thread's revenue grew by 243.37% to 1.506 billion yuan in 2025, with net losses reduced by 36.70% to 1.024 billion yuan [3] - Lingdian Electric Control's net profit increased by 745.02% to 135 million yuan, despite a slight revenue decrease of 0.17% to 1.194 billion yuan [4] - JinkoSolar reported a net loss of 6.786 billion yuan in 2025, a decrease of 6,959.50%, with total revenue falling by 29.18% to 65.492 billion yuan [16] Group 2: Corporate Actions - Huicheng is planning to issue H-shares and list on the Hong Kong Stock Exchange, with details still under discussion [5] - Zhongying Technology is planning to acquire at least 51% of Yingzhong Electric, which is expected to constitute a major asset restructuring [7] - Jierong Technology's actual controller is under investigation for suspected violations of information disclosure laws [6] Group 3: Market and Industry Trends - The AI industry is driving demand for computing power, benefiting companies like Cambrian and Moer Thread, which are expanding their market presence [1][3] - Muxi's GPU product shipments have significantly increased, reflecting strong market recognition and demand [2] - The global photovoltaic industry is facing price fluctuations and trade protection policies, impacting JinkoSolar's profitability [16]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) has received a drug registration certificate from the Philippines Food and Drug Administration for its Pregabalin capsules, allowing the product to be marketed [1] Group 1: Product Approval and Indications - Pregabalin capsules are primarily used for the treatment of postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, spinal cord injury-related neuropathic pain, and as an adjunctive treatment for epilepsy [1] - The product development for Pregabalin capsules was completed by Changzhou Pharmaceutical Factory in October 2019 [1] Group 2: Regulatory Approvals Timeline - The Pregabalin capsules received approval from the U.S. Food and Drug Administration in July 2021 [1] - The product obtained a drug registration certificate in Thailand in June 2025 and in Singapore in January 2026 [1] Group 3: Investment in R&D - The company has invested approximately RMB 2.19 million in research and development for the product's market entry in Southeast Asia, which includes Thailand, Singapore, Malaysia, and the Philippines [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) has received approval from the Philippines Food and Drug Administration for the marketing of Pregabalin capsules produced by its subsidiary, Changzhou Pharmaceutical Factory [1] Group 1: Product Approval - The Pregabalin capsules are primarily used for the treatment of postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, and neuropathic pain due to spinal cord injury, as well as for adjunctive treatment of epilepsy [1]

（股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於普瑞巴林膠囊獲得菲律賓藥品註冊證書的公告》僅 供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2026 年 2 月 28 日 上 海 醫 藥 集 團 股 份 有 限 公 司 香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） 关于普瑞巴林胶囊获得菲律宾药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（ ...